Results 51 to 60 of about 25,065,433 (389)

The protective role of the recombinant IL-2 in complex therapy of cystic ovarian endometriosis in patients of advanced reproductive age

Медицинский вестник Юга России, 2019
Objective: tto estimate the potential of the protective effect of recombinant IL-2 on the ovarian reserve of patients in advanced reproductive age after enucleation of a cystic ovarian endometriosis (COE).Materials and methods: Initially and over a year ...
E. I. Sokolova, I. I. Kutsenko, E. I. Kravtsova, S. K. Batmen   +3 more
doaj   +1 more source

Interleukin-2 gene promoter polymorphism (T330G) and lymphocyte platelet adhesion in influenza A (H3N2)

Журнал инфектологии, 2022
Introduction. Polymorphism of cytokine genes is a factor of susceptibility or resistance to infection, the development of the disease and a long, complicated course of influenza.Objectives.
G. A. Chuprova, A. N. Emel’yanova, A. S. Emel’yanov, Yu. A. Vitkovskii   +3 more
doaj   +1 more source

Role of IL-2 in cancer immunotherapy

Oncoimmunology, 2016
Interleukin-2 (IL-2) is one of the key cytokines with pleiotropic effects on immune system. It has been approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma.
T. Jiang, Caicun Zhou, S. Ren
semanticscholar   +1 more source

Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. [PDF]

Proceedings of the National Academy of Sciences, 1985
We demonstrate that purified interleukin 2 (IL-2) can directly upregulate IL-2 receptor expression on phytohemagglutinin-activated T lymphocytes maintained in culture until IL-2 receptor expression had markedly declined. The IL-2-induced increase in IL-2 receptor number is maximal within 12 hr, requires new RNA and protein synthesis, and is mediated by
Cynthia L. Drogula, Warren J. Leonard, Martin Krönke, Joel M. Depper, Warner C. Greene, Thomas A. Waldmann   +5 more
openaire   +3 more sources

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study [PDF]

, 2006
Objective: The objective of the trial was to evaluate in a pilot setting the safety and efficacy of interleukin-2 (IL-2) therapy when used without concomitant antiretroviral therapy as a treatment for HIV infection.
Abrams, Ann Sullivan, Carr, Carr, Carr, Christian Herzmann, Clive Loveday, Connelly, Crespo-Fierro, Davey, Davey, Davey, Dewar, Emery, Emery, Emery, George Janossy, H. Clifford Lane, Handan Wand, Jorge A Tavel, Kovacs, Kovacs, Lederman, Levy, Lisa Fosdick, Losso, Margaret A Johnson, Mark Nelson, Martin Fisher, Matthews, Mercolino, Mike Youle, Palella, Pillay, Pozniak, Richard T Davey, Ruxrungtham, Sean Emery, Sereti, Sereti, Smith, Stein, Urdea, Verbeke, Yeni   +44 more
core   +2 more sources

POSSIBLE MECHANISMS OF STIMULATORY EFFECTS OF MESENCHYMAL STROMAL CELLS UPON T CELL RECOVERY DURING CHEMOTHERAPY-INDUCED LYMPHOPENIA

Медицинская иммунология, 2014
The aim of present work was to evaluate the effect of mesenchymal stromal cells (MSCs) from lymphoma patients on the in vitro and in vivo homeostatic proliferation of lymphocytes.
E. V. Batorov, E. Ya. Shevela, M. A. Tikhonova, N. V. Pronkina, D. S. Batorova, I. V. Kryuchkova, T. I. Pospelova, A. A. Ostanin, E. R. Chernykh   +8 more
doaj   +1 more source

Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

Journal of Experimental Medicine, 2006
Abnormalities in CD4+CD25+Foxp3+ regulatory T (T reg) cells have been implicated in susceptibility to allergic, autoimmune, and immunoinflammatory conditions.
N. Seddiki, B. Santner‐Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, Michael Solomon, W. Selby, S. Alexander, R. Nanan, A. Kelleher, Barbara Fazekas de St. Groth   +11 more
semanticscholar   +1 more source

FEATURES OF INTERLEUKIN-2 AND INTERLEUKIN-4 PRODUCTION AND RECEPTION IN AUTOIMMUNE THYROID DISORDERS

Медицинская иммунология, 2014
. The aim of this study was to evaluate some immunopathogenic features of autoimmune thyropathies (autoimmune thyroiditis and Graves’ disease), in terms of IL-2 and IL-4 production and expression of specific surface receptors on blood lymphocytes.
T. V. Saprina
doaj   +1 more source

Interleukin-2 druggability is modulated by global conformational transitions controlled by a helical capping switch. [PDF]

, 2020
Interleukin-2 (IL-2) is a small α-helical cytokine that regulates immune cell homeostasis through its recruitment to a high-affinity heterotrimeric receptor complex (IL-2Rα/IL-2Rβ/γc).
De Paula, Viviane S, Garcia, K Christopher, Glassman, Caleb R, Jude, Kevin M, Nerli, Santrupti, Sgourakis, Nikolaos G   +5 more
core   +1 more source

In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection [PDF]

, 1987
We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in ...
Koszinowski, Ulrich H., Mutter, Wolfgang, Reddehase, Matthias J.   +2 more
core   +3 more sources